In addition, the observation that the KRASG60_A66dup and KRASE62_A66dup alleles are oncogenic despite impaired PI3K binding and Akt activation suggests that deep and sustained biochemical suppression by PI3K pathway inhibitors will likely be essential for clinical efficacy in RAS mutant cancers. The gene discussed is PIK3CA; the disease is cancer.